- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Nuklearmedizin, 58, 2, S. 150-
- Klassifikation
-
Medizin, Gesundheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2019
- Ereignis
-
Veröffentlichung
- (wo)
-
Stuttgart
- (wer)
-
Thieme
- (wann)
-
2019
- Urheber
-
Cytawa, W.
Bandurski, T.
Tran-Gia, J.
Schirbel, A.
Fukushima, K.
Wester, H. J.
Buck, A. K.
Lapa, Constantin Frederik Victor
- DOI
-
10.1055/s-0039-1683605
- URN
-
urn:nbn:de:bvb:384-opus4-629614
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:41 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cytawa, W.
- Bandurski, T.
- Tran-Gia, J.
- Schirbel, A.
- Fukushima, K.
- Wester, H. J.
- Buck, A. K.
- Lapa, Constantin Frederik Victor
- Universität Augsburg
- Thieme
Entstanden
- 2019
Ähnliche Objekte (12)
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms